Suchergebnisse - "Erdal, E"

PubPharm (36)

1

Tumour-specific hybrid nanoparticles in therapy of breast cancer

enthalten in: Journal of microencapsulation | 2024

von Kilicay, E. | Erdal, E. | Elci, P. | +2

2

Three-dimensional MRI-based treatment planning approach for non-invasive ocular proton therapy

enthalten in: Medical physics | 2021

von Fleury, E. | Trnková, P. | Erdal, E. | +9

3

Three‐dimensional MRI‐based treatment planning approach for non‐invasive ocular proton therapy

enthalten in: Medical Physics | 2021

von Fleury, E. | Trnková, P. | Erdal, E. | +9

4

Evaluation of electrocardiographic ventricular repolarization parameters in extreme obesity

enthalten in: Journal of electrocardiology | 2019

von Inanir, M. | Sincer, I. | Erdal, E. | +3

5

The Direct Cost-Components in Pulmonary Arterial Hypertension: An Expert Panel Approach for Estimation of Costs

enthalten in: Value in health | 2016

von Mogulkoc, N. | Okumus, G. | Yildizeli, B. | +5

6

The Direct Cost Components in Chronic Thromboembolic Pulmonary Hypertension in Turkey: An Expert Panel Approach for Estimation of Costs

enthalten in: Value in health | 2016

von Mogulkoc, N. | Okumus, G. | Yildizeli, B. | +5

7

Burden of Visual Impairment Due to Myopic Choroidal Neovascularisation (MCNV) in Turkey

enthalten in: Value in health | 2016

von Sar, C. | Malhan, S. | Oksuz, E. | +7

8

Cost-Effectiveness Of Riociguat For Treatment Of Patients With Inoperable Or Post-Operative Recurrent/Persistent Chronic Thromboembolic Pulmonary Hypertension (Cteph) In Turkey

enthalten in: Value in health | 2015

von Erdal, E. | Ozdemir, O. | Yildizeli, B. | +11

9

Cost-effectiveness of Aflibercept in the treatment of wet age-related Macular Degeneration in Turkey

enthalten in: Value in health | 2015

von Tunalioglu, A. | Ozdemir, O. | Eldem, B. | +11

10

The Cost-Effectiveness (CE) of Intravitreal Aflibercept (IVT-AFL) in the Treatment of Diabetic Macular Edema (DME) in Turkey

enthalten in: Value in health | 2015

von Saatci, A. | Ozmert, E. | Deger, C. | +12